Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMYT Amryt Pharma	$14.70 +0.1%	$14.64	$6.41 ▼ $14.77	$940.21M	0.84	757,360 shs	2.39 million shs
DAWN Day One Biopharmaceuticals	$6.32 -1.4%	$6.84	$6.08 ▼ $16.76	$649.73M	-1.3	1.13 million shs	1.50 million shs
MODV ModivCare	$3.24 -10.5%	$1.77	$0.87 ▼ $32.82	$51.96M	0.76	1.47 million shs	1.15 million shs
MRUS Merus	$53.10 +1.0%	$47.82	$33.19 ▼ $62.98	$3.64B	1.04	755,773 shs	601,480 shs

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMYT Amryt Pharma	0.00%	0.00%	0.00%	0.00%	0.00%
DAWN Day One Biopharmaceuticals	-1.40%	-5.25%	+0.48%	-23.21%	-52.80%
MODV ModivCare	-10.50%	+10.96%	+264.45%	+52.83%	-87.90%
MRUS Merus	+0.97%	-2.77%	+22.89%	+12.40%	-2.10%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMYT Amryt Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
DAWN Day One Biopharmaceuticals	1.6712 of 5 stars	3.6	0.0	0.0	0.0	2.3	2.5	0.0
MODV ModivCare	3.454 of 5 stars	3.1	2.0	0.0	4.5	1.1	0.8	0.6
MRUS Merus	3.3994 of 5 stars	4.6	3.0	0.0	0.0	3.3	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMYT Amryt Pharma	0.00	N/A	N/A	N/A
DAWN Day One Biopharmaceuticals	3.13	Buy	$30.57	383.73% Upside
MODV ModivCare	2.25	Hold	$8.38	158.49% Upside
MRUS Merus	3.14	Buy	$84.64	59.39% Upside

Current Analyst Ratings Breakdown

Latest MODV, DAWN, MRUS, and AMYT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/23/2025	MRUS Merus	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Outperform	$96.00 ➝ $110.00
5/19/2025	MRUS Merus	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00 ➝ $75.00
5/12/2025	MODV ModivCare	Barrington Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform
5/8/2025	MRUS Merus	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$91.00 ➝ $89.00
5/7/2025	DAWN Day One Biopharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$25.00
5/7/2025	DAWN Day One Biopharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $27.00
4/28/2025	MRUS Merus	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
4/9/2025	MRUS Merus	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$83.00 ➝ $83.00
4/3/2025	DAWN Day One Biopharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$36.00 ➝ $36.00
3/28/2025	MRUS Merus	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$109.00 ➝ $109.00
3/25/2025	DAWN Day One Biopharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$39.00 ➝ $27.00

(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMYT Amryt Pharma	$222.54M	4.22	$0.98 per share	14.98	$5.58 per share	2.63
DAWN Day One Biopharmaceuticals	$131.16M	4.88	N/A	N/A	$4.99 per share	1.27
MODV ModivCare	$2.79B	0.02	$14.09 per share	0.23	($2.69) per share	-1.20
MRUS Merus	$36.13M	101.72	N/A	N/A	$9.46 per share	5.61

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMYT Amryt Pharma	$1M	-$0.06	N/A	735.00	N/A	-8.19%	1.70%	0.75%	N/A
DAWN Day One Biopharmaceuticals	-$95.50M	-$0.71	N/A	N/A	N/A	-42.66%	-14.98%	-13.04%	7/8/2025 (Estimated)
MODV ModivCare	-$201.28M	-$16.10	N/A	20.25	N/A	-8.33%	13.64%	-1.19%	8/6/2025 (Estimated)
MRUS Merus	-$215.33M	-$4.08	N/A	N/A	N/A	-506.73%	-35.99%	-29.83%	7/30/2025 (Estimated)

Latest MODV, DAWN, MRUS, and AMYT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/14/2025	Q1 2025	MRUS Merus	-$1.17	-$1.40	-$0.23	-$1.40	$7.82 million	$26.49 million
5/6/2025	Q1 2025	DAWN Day One Biopharmaceuticals	-$0.46	-$0.35	+$0.11	-$0.35	$30.28 million	$30.76 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMYT Amryt Pharma	N/A	N/A	N/A	N/A	N/A
DAWN Day One Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A
MODV ModivCare	N/A	N/A	N/A	N/A	N/A
MRUS Merus	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMYT Amryt Pharma	0.64	1.57	0.94
DAWN Day One Biopharmaceuticals	N/A	10.62	10.55
MODV ModivCare	N/A	0.80	0.80
MRUS Merus	N/A	5.86	5.86

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMYT Amryt Pharma	71.31%
DAWN Day One Biopharmaceuticals	87.95%
MODV ModivCare	N/A
MRUS Merus	96.14%

Insider Ownership

Company	Insider Ownership
AMYT Amryt Pharma	5.66%
DAWN Day One Biopharmaceuticals	6.20%
MODV ModivCare	15.50%
MRUS Merus	4.57%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMYT Amryt Pharma	2,020	63.96 million	60.34 million	Not Optionable
DAWN Day One Biopharmaceuticals	60	101.36 million	95.08 million	Optionable
MODV ModivCare	23,675	14.35 million	12.13 million	Optionable
MRUS Merus	37	69.21 million	66.05 million	Optionable

MODV, DAWN, MRUS, and AMYT Headlines

Recent News About These Companies

Net Worth Advisory Group Buys Shares of 5,054 Merus (NASDAQ:MRUS)

June 14, 2025 | marketbeat.com

Harbor Capital Advisors Inc. Has $2.71 Million Stake in Merus (NASDAQ:MRUS)

June 12, 2025 | marketbeat.com

Bicara Therapeutics Looks To Reclaim Some Of The Spotlight From Merus

June 11, 2025 | seekingalpha.com

Merus’s Strategic Advancements and Promising Trials Justify Buy Rating with $92 Price Target

June 10, 2025 | tipranks.com

Underappreciated Potential of Merus’s Petosemtamab in Colorectal Cancer: Analyst Highlights Future Opportunities and Financial Stability

June 9, 2025 | tipranks.com

Why Merus N.V. (MRUS) Crashed On Wednesday

June 5, 2025 | msn.com

Why Merus N.V. (MRUS) Crashed On Wednesday

June 5, 2025 | insidermonkey.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Buys 14,544 Shares of Merus (NASDAQ:MRUS)

June 5, 2025 | marketbeat.com

Bank of America Corp DE Has $1.59 Million Stock Position in Merus (NASDAQ:MRUS)

June 5, 2025 | marketbeat.com

Merus (NASDAQ:MRUS) Shares Gap Down - What's Next?

June 4, 2025 | marketbeat.com

Merus Shares Slide on Stock Offering

June 4, 2025 | marketwatch.com

Merus N.V. Announces Pricing of $300 Million Public Offering of Common Shares

June 4, 2025 | quiverquant.com

Merus N.V. Announces Pricing of Public Offering of Common Shares

June 4, 2025 | globenewswire.com

Merus NV Announces Proposed Public Offering of Common Shares | MRUS stock news

June 3, 2025 | gurufocus.com

Merus N.V. Announces Proposed Public Offering of Common Shares

June 3, 2025 | globenewswire.com

Merus (NASDAQ:MRUS) Sets New 52-Week High - Should You Buy?

June 3, 2025 | marketbeat.com

'Our data is resonating far more with the people that matter,' Bicara CEO says amid Merus race

June 2, 2025 | fiercebiotech.com

Bicara Responds to Rival Merus With Early Survival Data at #ASCO25

June 2, 2025 | biospace.com

Merus’s Strong Clinical Data and Financial Stability Justify Buy Rating

June 2, 2025 | tipranks.com

Squarepoint Ops LLC Buys New Stake in Merus (NASDAQ:MRUS)

June 2, 2025 | marketbeat.com

Merus (NASDAQ:MRUS) Shares Up 9% - What's Next?

May 30, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MODV, DAWN, MRUS, and AMYT Company Descriptions

Amryt Pharma NASDAQ:AMYT

Amryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases. The company provides metreleptin, an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy; oral octreotide, a long-term maintenance therapy in acromegaly patients; and lomitapide, an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the Homozygous familial Hypercholesteraemia. Its development candidates include Oleogel-S10 for the cutaneous manifestations of Junctional and Dystrophic Epidermolysis Bullosa (EB), a rare and distressing genetic skin disorder affecting young children and adults; and AP103, a pre-clinical gene therapy for patients with dystrophic EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is headquartered in Dublin, Ireland.

Day One Biopharmaceuticals NASDAQ:DAWN

$6.32 -0.09 (-1.40%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$6.32 0.00 (0.00%)

As of 06/20/2025 04:20 PM Eastern

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.

ModivCare NASDAQ:MODV

$3.24 -0.38 (-10.50%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$3.17 -0.07 (-2.16%)

As of 06/20/2025 07:47 PM Eastern

ModivCare Inc., a technology-enabled healthcare services company, provides a suite of integrated supportive care solutions for public and private payors and their members. The company operates through four segments: Non-Emergency Medical Transportation (NEMT), Personal Care, Remote Patient Monitoring (RPM), and Corporate and Other. The company offers risk underwriting, contact center management, network credentialing, claims management, and non-emergency medical transport management services for Medicaid or Medicare eligible members, whose limited mobility or financial resources hinder their ability to access necessary healthcare and social services. It also provides in-home personal care services, such as bathing, personal hygiene, grooming, oral care, dressing, medication reminders, meal planning, preparation and feeding, housekeeping, transportation services, prescription reminders, and assistance with dressing and ambulation services through placing non-medical personal care assistants, home health aides, and skilled nurses primarily to Medicaid patients in need of care monitoring and assistance in performing daily living activities, including senior citizens and disabled adults. In addition, the company offers remote patient monitoring solutions, including personal emergency response systems, vitals monitoring, medication management, and data-driven patient engagement solutions. It serves federal, state, and local government agencies, MCOs, commercial insurers, private individuals, and health systems. The company was formerly known as The Providence Service Corporation and changed its name to ModivCare Inc. in January 2021. ModivCare Inc. was incorporated in 1996 and is headquartered in Denver, Colorado.

Merus NASDAQ:MRUS

$53.10 +0.51 (+0.97%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$54.01 +0.91 (+1.72%)

As of 06/20/2025 06:47 PM Eastern

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time